Upcoming Webinars

25July
25 July @ 01:00 pm - 02:00 pm

Update on Sarepta’s RNA-targeted technology platforms (PMO and PPMO)

Webinar details Dr. Gilmore O’Neill, Chief Medical Officer of Sarepta Therapeutics, Inc, will give a scientific overview of Sarepta’s RNA-targeted exon skipping technologies, PMO and PPMO. Dr. O’Neill will highlight the PPMO technology, designed to potentially improve upon the levels of dystrophin produced by PMO-induced exon skipping, and to potentially lead to more efficient dosing […]

WEBINAR ARCHIVES

Bamboo Therapeutics is a recently formed biotechnology company focused on advancing therapies for rare pediatric diseases of the central and neuromuscular systems. Bamboo was founded to advance the pioneering laboratory work of Dr. Jude Samulski, PhD, the former Director of the Gene Therapy Center at the University of North Carolina into human clinical trials. “Gene Therapy" describes the idea of introducing new genetic material into cells to correct an existing problem, often due to a disease-causing mutation. During the June 13, 2016 webinar, Dr. Samulski explained the basics of gene therapy and described Bamboo’s approach to developing a treatment for Duchenne; by utilizing a disabled virus to deliver a small, highly optimized version of the dystrophin gene systemically to skeletal and cardiac muscle.
Capricor Therapeutics and CureDuchenne hosted a webinar on November 3, 2015. The presentation discussed the HOPE-DUCHENNE Trial. The U.S. Food and Drug Adminstration has cleared Capricor's Investigational New Drug Application for the clinical development of CAP-1002 for the treatment of patients with Duchenne muscular dystrophy. The webinar provided an overview of the clinical trial which is being conducted at several sites in the U.S.
Capricor Therapeutics and CureDuchenne hosted a webinar on June 19, 2015. The presentation discussed the HOPE-DUCHENNE Trial. The U.S. Food and Drug Administration has cleared Capricor's Investigational New Drug Application for the clinical development of CAP-1002 for the treatment of patients with Duchenne muscular dystrophy.
On April 6, 2015, CureDuchenne and Dr. Kevin Flanigan held a webinar to provide an update on Duplication 2 Research for Duchenne Muscular Dystrophy. Click here to watch the recording of the webinar. You’ll be prompted to enter your name and email address to view the recording.
CureDuchenne and Capricor hosted a webinar on January 21, 2015 to discuss this promising research that addresses heart issues associated with Duchenne. Click here to watch the recording of the webinar. You’ll be prompted to enter your name and email address to view the recording.
1 2 3 4

Get Involved

Are you a medical professional or provider? Learn more about how you can help make a difference in the Duchenne community.

CLICK HERE